Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 708 of 6351
-
Could ketamine speed up depression relief in hospitalized patients?
Symptom relief Recruiting nowUnipolar major depressive disorder is the leading cause of disability worldwide. The most commonly used treatments for major depressive episodes (MDE) are antidepressant medications. However, they have limited efficacy and their onset of action is long, ranging between 2 to 6 wee…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 26, 2026 13:18 UTC
-
Inhaled drug offers new hope for stubborn lung infection
Disease control Recruiting nowTreatment of Mycobacterium xenopi (MX) lung disease is not-well- tolerated and concerned a growing number of patients, especially with chronic pulmonary diseases or immunosuppression. The outcome of these patients is poor, and treatment is very long. Indeed, this duration is base…
Phase 2 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Robot eye doctor could save Preemies' sight
Diagnosis CompletedThe purpose of the study is to evaluate the i-ROP DL system for autonomous ROP screening. To demonstrate the sensitivity and specificity of the i-ROP DL system on images obtained by healthcare providers in the neonatal intensive care unit (NICU) setting to detect more than mild R…
Sponsor: Siloam Vision • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
New drug combo aims to fight bile duct cancer
Disease control OngoingThis is a phase 3 study. All subjects are patients with unresectable locally advanced or metastatic biliary tract cancer (BTC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in combinati…
Phase 3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Gene therapy trial aims to halt Muscle-Wasting disease
Disease control OngoingThis is an interventional study to evaluate safety and efficacy of AAV-hSMN1 in spinal muscular atrophy patients.
Phase 1/2 • Sponsor: Lantu Biopharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Virtual reality could replace painkillers for bone marrow tests
Symptom relief By invitation onlyBone marrow (BM) examinations are performed in diagnostic workup of malignancies, in particular hematological diseases, and are frequently associated with significant pain, distress, and anxiety. Analgesic and sedative medications are given to alleviate discomfort. The aim of th…
Sponsor: Region Skane • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
New IV drug aims to control bleeding risk in rare blood disorder
Disease control Recruiting nowThe main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartig…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for colorectal cancer: amivantamab combo tested in 1,000 patients
Disease control Recruiting nowThe purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucov…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Higher aspirin dose may better protect pregnant women from dangerous hypertension
Prevention Recruiting nowThe overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated…
Phase 4 • Sponsor: Ohio State University • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Could a common arthritis drug shield transplant patients from a dangerous virus?
Disease control Recruiting nowPatients undergoing half-matched hematopoietic stem cell transplantation (HSCT) are at high risk of viral reactivation after bone marrow transplantation (BMT). The purpose of this study is to evaluate whether leflunomide can prevent cytomegalovirus (CMV) reactivation in these pat…
Phase 2 • Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for asian brain tumor patients: targeted pill slows cancer growth
Disease control OngoingThe objective of this study is to determine the efficacy, safety, and pharmacokinetics of vorasidenib in Asian participants with residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation. The study will begin with a safety lead-in (SLI) phase and then will transition to …
Phase 3 • Sponsor: Servier • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Experimental drug chidamide targets Hard-to-Treat blood cancer
Disease control Recruiting nowThis is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.
Phase 2 • Sponsor: Great Novel Therapeutics Biotech & Medicals Corporation • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug combo aims to wipe out leukemia cells in High-Risk patients
Disease control OngoingThe goal of this clinical trial is to test daratumumab in adult very high risk T-lineage lymphoblastic leukemia. The main question it aims to answer is wether the addition of daratumumab daratumumab to the national standard of care is able to increase the rate of MRD-negative pa…
Phase 2 • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New pill shrinks lung tumors before surgery in early trial
Disease control OngoingTo assess the efficacy and safety of sunvozertinib as neoadjuvant therapy in patients with stage II-IIIB non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins).
Phase 2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New valve device could fix leaky heart valve without open surgery
Disease control Recruiting nowThe primary objective of this study is to assess the safety and efficacy of the J-Valve Transfemoral (TF) System in patients with symptomatic, severe (grade 3 or 4), native aortic valve regurgitation (AR) and AR-dominant mixed aortic valve disease, who are judged by a multi-disci…
Sponsor: JC Medical, Inc., an affiliate of Edwards Lifesciences LLC • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for tough leukemia: experimental drug targets resistant cancers
Disease control Recruiting nowThe aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted standard treatment, including a sub…
Phase 1 • Sponsor: Nerviano Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo shows promise for tough lung cancer
Disease control CompletedThis is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of ivonescimab combined with irinotecan liposome for relapsed small cell lung cancer, who progressed on PD-(L)1 -based first-line therapy.
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New shingles vaccine shows promise in Head-to-Head trial
Vaccine OngoingThe goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles). Subjects will be randomized to receive either JCXH-105 or Shingrix.
Phase 2 • Sponsor: Immorna Biotherapeutics, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:23 UTC
-
New hope for psoriatic arthritis sufferers: experimental drug sonelokimab enters final testing phase
Disease control Recruiting nowThis is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Own stem cells could improve movement in kids with cerebral palsy
Disease control Recruiting nowThis clinical trial aims to evaluate the effectiveness of autologous bone marrow mononuclear cell transfusion in treating cerebral palsy caused by cerebral hypoxia. The key questions the study seeks to answer are: * What is the safety profile in terms of adverse events (AE) and…
Phase 2 • Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC